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Abstract  
Giant cell arteritis (GCA) is the most common form of vasculitis in adults. Cranial 
manifestations are typical clinical features of this vasculitis. Sometimes the presenting 
symptoms are nonspecific and, in some cases, large-vessel involvement may prevail. 
Polymyalgia rheumatica is a frequent manifestation that in some cases may be the 
presenting symptom of GCA. Visual complications, in particular the risk of blindness, 
constitute the most feared manifestations of GCA. Prompt recognition of this vasculitis 
is required to avoid irreversible complications. Prednisone/prednisolone at a dose of 40-
60 mg/day is the cornerstone therapy in GCA. Glucocorticoids lead to rapid 
improvement of symptoms and may reduce the risk of irreversible visual loss. However, 
relapses are common when the prednisone dose is tapered. Therefore, additional 
therapies are required in relapsing GCA or when a rapid reduction of glucocorticoids is 
needed. The most widely used conventional immunosuppressive drug is methotrexate 
Adjunctive treatment with methotrexate may decrease the risk of relapses and reduce 
glucocorticoid exposure. However, comprehensive reviews indicate that the efficacy of 
methotrexate in GCA is modest. The experience with other conventional 
immunosuppressive drugs in GCA patients is scarce. In some cases, the new biologic 
agents are required. Among them, the most frequently used is the recombinant 
humanized anti-IL-6 receptor antibody tocilizumab. It improves clinical symptoms, 
reduce the cumulative prednisone dose and the frequency of relapses in GCA patients. 
However, anti-tumor necrosis factor-α therapy is not useful in GCA. Promising results 
on other biologic agents, such as abatacept, ustekinumab or anakinra, require further 
confirmatory studies.  
Keywords: anti-IL6-receptor tocilizumab, biologic agents, giant cell (temporal) 
arteritis, methotrexate, polymyalgia rheumatica, prednisone, relapses. 
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1. Introduction 
Giant cell arteritis (GCA), also called temporal arteritis, is a granulomatous vasculitis 
affecting mainly large and middle-sized arteries, in particular the branches of the 
proximal aorta (1).  GCA is the most common form of vasculitis in adults, in particular 
in Western countries (2). It almost exclusively affects patients aged 50 years or older 
(2,3). The incidence increases in the older age groups being more common in the eighth 
decade of life (4).  
Cranial manifestations are common, being the result of the arteritic involvement of 
branches derived of the external carotid artery (5). They include new onset headache, 
generally bitemporal, scalp tenderness, facial pain, jaw and more rarely tongue 
claudication, and nonproductive cough (5). However, the most feared manifestation is 
the development of blindness, which in most cases is the result of the vasculitis 
involvement of arteries derived from the ophthalmic artery that, in turn, is a branch of 
the internal carotid artery (6-8). Strokes, mainly due to the vasculitis involvement of the 
vertebrobasilar territory, are not exceptional complications (6,9). Polymyalgia 
rheumatica, a condition that is also more frequents in individuals older than 50 years 
(1,10,11), may be the presenting manifestation of GCA (11,12,13). Polymyalgia 
rheumatica features are observed in up to 50% of the patients with GCA (5,11). The 
musculoskeletal manifestations in patients with isolated polymyalgia are similar to 
those observed in patients with polymyalgia rheumatica associated with the typical 
cranial pattern of GCA (14). However, patients with isolated polymyalgia rheumatica 
often have less severe inflammatory response than those with polymyalgia rheumatica 
associated with GCA (14). 
Although cranial ischemic manifestations are the hallmark features of GCA, recent 
studies have shown a growing number of patients with predominant extracranial large-
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vessel vasculitis involvement, often not associated with the classic cranial 
manifestations (15,16). Imaging techniques, such as the fluorine-18-fluorodeoxyglucose 
(18F-FDG) positron emission tomography/computed tomography (FDG-PET/CT)-scan, 
have confirmed that extra-cranial large-vessel vasculitis is not uncommon in GCA (17).  
 The physical examination often shows abnormalities of the temporal arteries, such as 
thickening, tenderness, beading or reduced pulsation (5,18). Pulse deficits due to 
peripheral arterial vasculitis may be observed (18).  
Patients with GCA have a higher risk of aneurysms and dissection over the course of the 
disease, especially in the thoracic segment (19,20). 
High erythrocyte sedimentation rate (ESR) and/or C reactive protein (CRP) are 
observed in the majority of patients (21). In some cases, non-specific features, 
unexplained anemia or fever of unknown origin may be the only features of a silent 
“occult GCA” (22,23). 
Table 1 summarizes the main clinical features that may alert the clinicians on the 
presence of GCA.  
In patients with the classic cranial pattern of the disease a positive temporal artery 
biopsy is considered the gold-standard for diagnosis (24). It shows an inflammatory 
infiltrate with the presence of multinucleated giant cells between the media and intima 
layers in 50% of the cases and disruption of the internal elastic lamina, ultimately 
leading to partial or complete obstruction of local arterial blood flow. A temporal artery 
ultrasound may be a good alternative to the temporal artery biopsy in these patients 
(25).  
Imaging techniques, such as MRI or computed tomography-angiography or PET/CT-
scan, can help to diagnose patients with predominant extracranial features (25). Experts 
in the field consider that in some cases imaging techniques may also be used to monitor 
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response to treatment (26). Graphical abstract shows the main clinical differences 
between the classical (cranial) and the extracranial phenotypes of GCA. 
 
2. Pathogenesis of GCA 
The precise etiology and pathogenesis of GCA are not well known. Experts in the field 
consider that GCA is the results of unknown environmental factors in individuals 
genetically predisposed. GCA affects mainly large- and medium-sized vessels leading 
to vascular inflammation and granuloma formation, leading in the long run to intimal 
hyperplasia and occlusion of the arterial lumen along with destruction of the vessel 
wall. The vascular damage is responsible of the development of vascular complications 
such as ischemic events and aneurysms (27). 
There are a number of studies emphasizing the role of the genetic background in the 
susceptibility to GCA. The particular relevance is the strong association between GCA 
and the human leukocyte antigen (HLA) region (28,29). A recent immunochip approach 
study assessing 1651 GCA patients from six different countries of European ancestry, 
and 15306 unrelated controls confirmed that class II HLA was the genomic region with 
the strongest association with GCA (30). Outside the major histocompatibility complex 
(MHC) region, variants in PTPN22 locus (30) and other genes related to vascular 
response to inflammation and vascular remodeling, such as plasminogen and prolyl 4-
hydroxylase subunit alpha 2, are also interestingly associated with GCA risk (31). Other 
gene polymorphisms have been associated with increased risk of severe ischemic 
complications, including blindness (32,33). Besides a genetic component, 
environmental factors and epigenetic modifications are thought to be involved in the 
pathogenesis of GCA (Figure 1). In this regard, several studies have suggested the 
potential influence of different bacterial strains (such as Chlamydia pneumonia and 
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Burkholderia), and viruses (cytomegalovirus, parvovirus B19, herpes simplex virus and 
human parainfluenzae 1) in the induction of GCA (34-36). Unfortunately, these studies 
often yielded contradictory results and the role of infectious agents has not been 
confirmed in larger cohort studies, raising concern about the strong implication of 
infectious agents in the pathogenesis of GCA. 
It is plausible to think that aging itself may be implicated in the pathogenesis of the 
disease, probably as a result of the influence of environmental effects and epigenetic 
modifications that occur throughout the life of the patient (37). Because of that, 
differences in the DNA methylation level of several genes have been reported in 
temporal arteries from GCA patients when compared with non-GCA patients (38). 
Besides, aging induces structural changes and biochemical modifications of matrix 
proteins into the arterial walls, which could activate immunization against arterial auto-
antigens leading to GCA development (37).  
Regardless of the trigger factors, it is known that inflammation in GCA starts in the 
adventitia and later spreads into the inner layers of the vessel wall. The adventitia is 
abundant in resident macrophages and dendritic cells (DCs) expressing Toll-like 
receptors, which are abnormally activated in this vasculitis via pathogen-associated 
molecular patterns (PAMPs) or microorganism-associated molecular patterns 
(MAMPs), leading to the production of pro-inflammatory cytokines such as interleukin 
(IL)‑ 1 and IL‑ 6 as well as the activation of T cells (27). Furthermore, DCs express 
high levels of class-II MHC and co-stimulatory molecules (CD80 and CD86), making 
them able to activate CD4+ T lymphocytes (39,40).  
The importance of CD4+T cells in the pathogenesis of GCA is suggested by the fact 
that their depletion in the model of SCID mice engrafted with GCA arteries strongly 
decreases vasculitis lesions (41). Once recruited in the arterial wall, CD4+ T cells are 
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activated by DCs and then, they are polarized toward Th1 and Th17 cells, depending on 
the predominant pro-inflammatory microenvironment (IL-12, IL-18, IL-23, IL-6 and IL-
1β cytokine profiles). Th1 cells are generated in the presence of IL-12 and IL-18 and 
produce IFN-γ, whereas Th17 cells are generated in the presence of IL-6, IL-1β and IL-
23 producing IL-17 (42). The strong infiltration of Th1 and Th17 cells into the arterial 
wall is responsible for the production of large amounts of IFN-γ and IL-17, respectively. 
Interestingly, IFN-γ induces the production of several chemokines (CCL2, CXCL9, 
CXCL10 and CXCL11) by vascular smooth muscle cells (VSMC) (43). CCL2 leads to 
the recruitment of monocytes, which express its receptor (CCR2) and then merge to 
form multinucleated giant cells, the hallmark of GCA (43). CXCL9, CXCL10 and 
CXCL11 trigger the recruitment of more immune cells, particularly Th1 and CD8+ T 
cells, auto-amplifying its inflammatory effect, leading to the production of more IL-17 
and IFN-γ, as well as other cytotoxic molecules such as granzymes and perforin (44). 
Once recruited in the arterial wall, IFN-γ-stimulated monocytes differentiate into 
macrophages. Macrophages produce more IL-6, IL-1β and TNF-α, which intensify the 
local inflammatory response and are responsible for the constitutional syndrome and 
general signs of GCA. In the media, IFN-γ-activated macrophages produce mediators 
which are toxic for the arterial tissue. Reactive oxygen species cause lipid peroxidation 
of phospholipids, nitric oxide (NO) produced by the induced NO-synthase (iNOS) 
triggers nitration of endothelial proteins, and matrix metalloproteinase-2 (MMP-2) and 
MMP-9 produced by VSMC and macrophages destroy cellular matrix proteins, causing 
the destruction of the media and digestion of the internal elastic lamina (45).  
Macrophages, giant cells or injured VSMC also produce growth factors and other 
mediators, essentially platelet-derived growth factor (PDGF) and vascular endothelial 
growth factor (VEGF), contributing to intimal hyperplasia, vascular occlusion and 
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remodeling. VEGF is responsible for endothelial cell growth, neo-angiogenesis and 
“vasa vasorum” formation (46). In addition, IL-33, an alarmin belonging to the IL-1 
family, is overexpressed in GCA arteries and is probably involved in the pathogenesis 
of angiogenesis-dependent inflammation in GCA (47). In addition, PDGF is implicated 
in the proliferation and migration of VSMC toward the intima, also resulting in intimal 
hyperplasia. Finally, endothelins may also contribute to the pathogenesis of GCA by 
promoting inflammation, increasing the sensitivity of the lesion to vasoconstriction, 
increasing VSMC proliferation and stimulating the migration of VSMC towards the 
intimal layer, all of them contributing to intimal hyperplasia and vascular occlusion 
(48,49).  
Furthermore, VSMCs accumulate in the media of arteries of patients with GCA 
acquiring pro-inflammatory properties. Indeed, activated macrophages and VSMCs 
themselves produce several growth factors (PDGF, TGF-β, endothelin-1, nerve growth 
factor, brain-derived neurotrophic factor and the neurotrophin co‑ receptor sortilin), 
inducing the migration of VSMC into the intima and their differentiation into 
myofibroblasts, which synthetize matrix proteins. This process finally leads to intimal 
hyperplasia and vascular occlusion. VSMC also produce MMPs such as MMP-9 and 
especially MMP-2, which allow them to destroy the media and the internal elastic 
lamina (50,51). Figure 1 shows the main molecular and cellular findings in the 
pathogenesis of GCA. 
Other kinds of immune deregulation in T-cells may also explain the immune activation 
observed in GCA. Programmed death-1 (PD-1) expressed by activated T cells and its 
ligation to PD-L1 or PD-L2, which are expressed by antigen presenting cells, induces T-
cell apoptosis, T-cell anergy and the production of IL-10 by T cells or their polarization 
into Treg lymphocytes. In this line, a defect in the immunoprotective PD-1/PD-L1 
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immune checkpoint has recently been reported in GCA patients (52). The implication of 
immune checkpoints in GCA pathogenesis is also emphasized by the recently proved 
efficacy of abatacept for the treatment of GCA (53). 
 
3. Treatment of giant cell arteritis  
The probability of visual recovery is low when blindness is established (7,54).  
Therefore, treatment should not be delayed if GCA is suspected. Glucocorticoids are the 
cornerstone of the therapy in GCA treatment (55-57).  
Conventional immunosuppressive drugs, mainly methotrexate (MTX), can be used as 
glucocorticoid-sparing agents, thus reducing their adverse effects. However, different 
studies yielded conflicting results in terms of safety and clinical benefit of conventional 
immunosuppressive drugs in GCA (57,58). Low-dose aspirin has been recommended to 
reduce the risk of associated cardiovascular events (19,59,60). Open-label studies and 
clinical trials have shown that biologic agents, in particular the anti-interleukin (IL)-6 
receptor, tocilizumab, a humanized monoclonal antibody, may lead to maintained 
glucocorticoid-independent remissions (61-64). Table 2 shows the main drugs used for 
the management of GCA, while Figure 2 shows the therapeutic escalation in this 
disease, with the different options currently available. 
In the next sections, we have conducted a comprehensive and critical review on the 
classic management as well as the new therapies used in patients with GCA. 
3.1. Glucocorticoids: The drugs of choice 
Glucocorticoids are the gold-standard therapy to improve symptoms and reduce the risk 
of severe ischemic complication in patients with GCA (55). Unlike patients with 
isolated PMR, in whom the initial dose of prednisone/prednisolone recommended to 
achieve rapid improvement of symptoms ranges between 12.5 and 25 mg/day (11,65), 
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high-dose glucocorticoid therapy is needed to improve symptoms and accomplish 
disease remission in patients with GCA (66). The initial dose of 
prednisone/prednisolone in GCA ranges between 40-60 mg/day for 3-4 weeks (55,57). 
Clinical practice indicates that prednisone doses lower than 20 mg/day given at the time 
of GCA diagnosis do not prevent the development of visual ischemic complications 
(67). 
Most patients experience improvement of cranial symptoms, such as headache, facial 
pain, jaw claudication or scalp tenderness, within the first 24 to 72 hours after the onset 
of glucocorticoid therapy. It is also the case for polymyalgia rheumatica features. 
We and others recommend using an initial prednisone dose of 40 mg/day in GCA 
patients without severe ischemic complications (57,68,69). Experts from the EULAR 
suggested using an initial dose of prednisolone of 1 mg/kg/day (maximum 60 mg/day) 
(66). Most clinicians agree on the use of an initial prednisone/prednisone dose of 60 mg/ 
day or the initial administration of intravenous methylprednisolone pulse therapy (1g 
daily for 3 consecutive days) if patients present with severe ischemic manifestations, in 
particular if they have visual impairment (8,26). However, few patients experience 
visual recovery if they present with visual loss lasting more than 24-48 hours (7,70). 
Therefore, intensive glucocorticoid therapy must be started as soon the diagnosis of 
GCA is suspected to reduce the risk of blindness.  
A study showed a beneficial effect of high-dose intravenous methylprednisolone as 
induction therapy for GCA (71). It included 27 patients with GCA confirmed by a 
positive temporal artery biopsy. Patients were randomized to receive induction therapy 
with intravenous methylprednisolone (15 mg/kg ideal body weight/day) (n= 14) or 
intravenous saline for 3 consecutive days (n= 13). All patients started on an initial 
prednisone dose of 40 mg/day. The median total cumulative oral prednisone dose 
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received by the group of intravenously glucocorticoid-treated patients at week 78 was 
5,636 mg whereas the median total cumulative oral prednisone dose received by the 
placebo‐ treated group at week 78 was 7,860 mg. The difference was statistically 
significant. The subgroup of GCA patients initially treated with intravenous 
methylprednisolone had faster tapering of oral prednisone and higher rate of patients 
who achieved sustained remission of the disease after discontinuation of prednisone 
therapy. Therefore, the authors of the study concluded that induction therapy with 
high‐ dose pulse intravenous methylprednisolone may yield long‐ term benefit 
allowing a lower total oral prednisone dose. However, there were some limitations in 
this study. The most important was that the initial high-dose intravenous 
methylprednisolone received by the 14 patients was not included in the latter 
calculation. It clearly underestimated the cumulative glucocorticoid dose received by 
the subgroup of intravenously treated GCA patients. In addition, the small sample size 
could have affected the final outcomes. Moreover, the mean CRP protein level at 
baseline was lower in the methylprednisolone‐ treated group (3.43 mg/dl versus 5.16 
mg/dl), and fewer patients in this group had weight loss, fever, or scalp tenderness. 
Although these clinical and laboratory differences were not statistically significant, they 
may represent a difference in terms of disease severity (71). In this regard, data from 
another study did not support the long-term glucocorticoid -sparing effect of 
intravenous methylprednisolone in the management of non-complicated patients with 
GCA. It included 164 patients treated with pulse methylprednisolone at a dosage lower 
than that used in the former study (72).   
In general, acute phase reactants (ESR and CRP) become normal in most patients within 
2 to 4 weeks after the onset of the glucocorticoid therapy (55,57,68). Then, the 
glucocorticoid dose can be gradually tapered (66). As previously reported (57), we 
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usually taper 5 mg of prednisone every 2-4 weeks up to 25 mg/day, generally every 2 
weeks. Then, we perform prednisone reduction more slowly by 2.5 mg every 2-4 weeks 
until a prednisone dose of 10 mg/day is reached. Afterwards, we taper prednisone dose 
by approximately 2.5 mg every 2 months (57,73). This way of prednisone tapering, 
which was based on our experience with 287 patients with GCA confirmed by a 
positive temporal artery biopsy (9), does not correspond with the EULAR 
recommendations (66). EULAR experts recommended a faster reduction of the 
prednisone dose, reaching 10-15 mg/day of prednisone at week 12 if the patients have 
not suffered relapses of the disease (66). This recommendation was based on the high 
number of side effects, such as such as diabetes mellitus, fractures, gastrointestinal 
bleeding, hypertension, cataracts and infections, reported in some studies on GCA 
patients undergoing prolonged use of glucocorticoids (74,75). 
Close monitorization of GCA patients during the follow-up, searching for relapses of 
the disease and assessing routine laboratory markers of inflammation, is required (57).  
In general, clinicians gradually taper the glucocorticoids in the follow-up if patients 
have no symptoms of GCA and the acute phase proteins ESR and CRP are normal 
(73,76). At the time of tapering prednisone, it is important to keep in mind that alternate 
day glucocorticoid use should not be performed because it often leads to a relapse of the 
disease (26,66). 
Typical relapses of GCA, in patients who undergo glucocorticoid therapy or who have 
discontinued the treatment, occur with an important rise of ESR (≥ 40 mm/1st hour) and 
they are associated with disease-related manifestations such as headache or other cranial 
manifestations, polymyalgia rheumatica, fever or constitutional symptoms. However, 
relapses of the disease are often associated with only mild elevation of ESR. Therefore, 
in practical terms relapses can be considered to be present in patients receiving 
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glucocorticoids or in those who have discontinued this therapy when clear and 
worsening symptoms occurred with an ESR equal to or greater than 20 mm/1st hour 
(77). A population-based study disclosed that 71 (41%) of 174 biopsy-proven GCA 
patients experienced relapses of the disease. The total duration of glucocorticoid therapy 
was significantly longer in those patients who had relapses (77). In keeping with these 
results, 57 (45.6%) of 125 patients from Olmsted County (Minnesota, USA) diagnosed 
with GCA between 1950 and 1991 had relapses (75). One hundred and three (86%) of 
them suffered adverse events associated with glucocorticoid use. A higher cumulative 
dose of glucocorticoids was associated with the development of adverse glucocorticoid 
side effects (75).  
 
3.2. Glucocorticoid-sparing agents  
Patients with GCA often have a chronic-relapsing course and may require 
glucocorticoids for several years. The high frequency of relapses and side effects related 
to glucocorticoids justify the use of glucocorticoid-sparing agents in some patients with 
GCA. Another situation that may require the use of glucocorticoid-sparing agents is in 
glucocorticoid resistant polymyalgia rheumatica patients, in whom a large vessel 
vasculitis is disclosed by imaging techniques, such as PET/CT scan (17).   
A glucocorticoid-sparing agent is considered to be effective if it allows the clinician to 
shorten the duration of the glucocorticoid therapy and decrease the side effects related 
to prolonged use of glucocorticoids.  
 
3.2.1. Conventional immunosuppressive drugs 
Conventional immunosuppressive drugs have been used in relapsing patients or in those 
severe glucocorticoid-related side effects (57,66).  MTX is the conventional 
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immunosuppressive drug most commonly used for the management of refractory GCA 
(66) (Figure 2). However, the efficacy of this drug in GCA is modest (34). There are 
three randomized controlled trials on MTX as adjunctive therapy to glucocorticoids (58-
60). The first trial included 21 patients with GCA treated with high-dose glucocorticoids 
along with MTX (n=12) or placebo (n=9) (78). Results were negative since there were 
not significant differences between the MTX and the placebo groups in the cumulative 
glucocorticoid dose, number of weeks to achieve glucocorticoid discontinuation, weeks 
required to taper prednisone to less than 10 mg/day and bone mineral density in lumbar 
spine or hip at one year (78). 
A second trial conducted in a single center included 50 patients with GCA confirmed by 
a positive temporal artery biopsy. Patients had received a dose equal to or higher than 
10 mg/prednisone/day for less than 2 weeks prior to the onset of the study. A single 
dose of 10 mg/week of oral MTX or placebo was started and maintained throughout the 
period of study. Discontinuation of MTX and placebo was allowed after 24 months of 
follow-up if the patient was in clinical remission. In this study, the initial dose of 
prednisone was 60 mg/day, which was gradually tapered (79). MTX use was associated 
with a significant decrease in the frequency of relapses of GCA (79). This was the first 
trial showing that treatment with MTX and glucocorticoids is safer and more effective 
than glucocorticoid therapy alone to reduce the frequency of relapses of GCA. 
The third randomized clinical trial on MTX in GCA was a multicenter study that 
enrolled 98 patients from different centers (80). The initial dose of prednisone was 1 
mg/kg/day (maximum 60 mg/day) administered along with 0.15 mg/kg/week MTX 
(increased to 0.25 mg/kg/week, for a maximum weekly dose of 15 mg) or placebo. The 
median dose of MTX was 15 mg/week. Unlike the former study (79), the use of MTX 
along with glucocorticoids did not yield benefits in GCA patients (80). The frequency 
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of treatment failure after 12 months was similar in both groups (80). No differences 
between MTX and placebo groups in the cumulative glucocorticoid dose were observed 
(80).   
A meta-analysis of these three-randomized placebo-controlled trials yielded a modest 
role of MTX (10-15 mg/week) to reduce the frequency of relapses and decrease the 
cumulative prednisone dose (81).  
The experience with other conventional immunosuppressive drugs in GCA patients is 
small and of limited relevance (57). With respect to this, a double-blind randomized 
placebo-controlled study in patients with GCA or polymyalgia rheumatica suggested 
that azathioprine might be useful to reduce glucocorticoid requirement (82). However, 
the number of patients included in this study (n= 31) was small to draw strong 
conclusions. Another study that included 12 patients with polymyalgia rheumatica and 
11 with GCA highlighted the potential efficacy of leflunomide as a glucocorticoid-
sparing agent (83). However, the experience with leflunomide in GCA is limited. Other 
drugs such as cyclosporine A, hydroxychloroquine or dapsone did not show beneficial 
effects as glucocorticoid-sparing agents in patients with GCA (58). Yates et al. 
conducted an elegant study that included a meta-analysis that analyzed the efficacy of 
different conventional immunosuppressive drugs. They concluded that the efficacy and 
safety of prednisone/prednisolone alone is in most cases similar to that derived from the 
use of glucocorticoids with adjunctive immunosuppression in patients with GCA (58). 
  
3.2.2. Biologic agents and other new therapies for GCA 
3.2.2.1. Anti-tumor necrosis factor (TNF) agents 
Classic studies emphasized the role of proinflammatory cytokines in the pathogenesis of 
GCA (84,85). Tumor necrosis factor (TNF)-alpha was found in the temporal artery 
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biopsies of patients with GCA (84-86) and different studies emphasized the efficacy of 
anti-TNF therapy in patients with inflammatory arthritis. However, anti-TNF therapy 
was not found to be effective to achieve remission in patients with GCA. 
The most relevant study on anti-TNF agents in GCA was a phase 2 study, randomized, 
double-blind, placebo-controlled trial to assess the efficacy of the chimeric monoclonal 
antibody-infliximab in newly diagnosed GCA patients (87). Forty-four patients that 
achieved resolution of symptoms and normalization of ESR following treatment with 
40-60 mg/day of prednisone/prednisolone were recruited in this study. Patients had to 
be in remission of the disease for at least 1 week before randomization. They received 
an initial dose of 40-60 mg/prednisone/day and were randomized to receive either 
placebo (n=16) or infliximab 5 mg/kg/infusion (n=28) at baseline (week 0) and at weeks 
2, 6, 14, 22, 30, 38 and 46. Infliximab did not yield significant reduction in the 
cumulative doses of prednisone or in the number of patients free of relapses after 22 
weeks of follow-up (87). 
Experience with other TNF-antagonists has been scarce and the outcome in terms of 
efficacy disappointing. With respect to this, a study using the human anti-TNF 
monoclonal antibody adalimumab administered for 10 weeks did not show efficacy to 
reach remission with a dose of less than 0.1 mg/kg of prednisone at 6 months. 
Adalimumab-treated patients had more infections (88). Information on etanercept a 
fully soluble, human dimeric fusion protein, which functions as a TNF inhibitor by 
competitively binding to TNF and preventing its activation of the inflammatory 
cascade, is also limited to a pilot study that did not confirm efficacy in patients with 
GCA (89).   
3.2.2.2. Interleukin (IL)-6 inhibitors 
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IL-6 is a pivotal proinflammatory cytokine that promotes the synthesis of acute phase 
proteins. It also promotes the transition from acute to chronic inflammation. IL-6 is 
produced in the inflamed arteries of patients with GCA (90). It is also expressed in the 
monocytes of these patients (91). GCA patients have increased IL-6 serum levels 
(85,92). IL-6 concentration is closely related to disease activity and the CRP level. 
Persistence of high serum IL-6 levels suggests the presence of disease activity in 
glucocorticoid-treated patients with GCA (92). In this regard, IL-6 serum levels 
correlate with disease activity better than ESR. 
The first data on the relevance of IL-6 in GCA were reported by Dasgupta and Panayi 
(93). They showed that the use of glucocorticoids led to a rapid reduction of the levels 
of IL-6 in patients with GCA (93). Since the decrease of IL-6 in serum was associated 
with a reduction in disease activity, the blockade of IL-6 was considered to be a good 
therapeutic option in GCA (94).  
Single cases and small series showed that the anti-IL-6 receptor (anti-IL-6R) 
tocilizumab was effective in both newly diagnosed and relapsing patients with GCA 
(95,96). Tocilizumab is a monoclonal antibody that competitively inhibits the binding of 
IL-6 to its receptor. The inhibition of the entire receptor complex prevents IL-6 signal 
transduction to inflammatory mediators that summon B and T cells (97). This biologic 
agent has a nonlinear pharmacokinetic profile. 
A retrospective, open-label, study that included 22 patients also showed that 
tocilizumab was useful in GCA patients with refractory and relapsing disease (61). 
Patients from this study had previously been treated with high dose prednisone and in 
most cases (n= 19) with conventional immunosuppressive drugs and/or biologic agents. 
They were treated with intravenous tocilizumab (8 mg/kg/month) (61). Nineteen of the 
22 patients achieved rapid and maintained clinical response that correlated with a 
  
Biochem Pharmacol                                   Treatment of GCA                                     González-Gay et al  18 
 
statistically significant reduction of CRP and ESR (61). Significant reduction in the 
prednisone dose was obtained (61). Prednisone was successfully tapered in 20 of the 22 
patients. In keeping with these positive findings, another retrospective multicenter study 
showed beneficial effect of tocilizumab in 28 of 34 patients with GCA (98).  
Two placebo-controlled trials fully confirmed that the anti-IL-6R tocilizumab is a useful 
therapy in patients with GCA (62,63). The first of them was a phase 2 study in which 
the assessor judging clinical response was not blinded to the laboratory findings, being 
allowed to make changes in the treatment during the follow-up based on laboratory 
alterations (62). The study included 23 newly diagnosed and 7 with relapsing patients 
with GCA who were randomized to receive intravenous tocilizumab at a dose of 8 
mg/kg every 4 weeks plus prednisolone (n=20 patients) or placebo infusion every 4 
weeks plus prednisolone (n=10). The primary endpoint was the percentage of patients 
who achieved complete remission at a prednisolone dose of 0.1 mg/kg/day at week 12. 
Seventeen of the 20 patients treated with intravenous tocilizumab achieved complete 
remission whereas it only occurred in 4 of the 10 placebo-treated patients (62). Rapid 
glucocorticoid tapering followed by discontinuation after 36 weeks from the onset of 
therapy was achieved in tocilizumab-treated patients. The cumulative prednisolone dose 
at 52 weeks was also significantly lower in the tocilizumab group (43 mg/kg) than in the 
placebo group (110 mg/kg). Relapse-free survival at 52 weeks was significantly higher 
in the tocilizumab-treated patients (85%) than in those treated with placebo (20%) (62). 
Nevertheless, relapses were reported once that tocilizumab was discontinued (62). 
Seven (35%) patients from the tocilizumab-treated group and 5 (50%) from the placebo 
group had serious adverse events (62). Although this study confirmed the efficacy of 
tocilizumab to induce remission, prevent relapses, and decrease the cumulative 
glucocorticoid dose, the use of CRP along with the clinical response as a combined final 
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endpoint could have overestimated the actual number of remissions, because 
tocilizumab is very effective to decrease the levels of CRP (62). 
The use of the anti-IL-6R monoclonal antibody-tocilizumab in GCA was fully 
supported by data from a randomized, double-blind, placebo-controlled, phase 3 trial, 
the Giant-Cell Arteritis Actemra (GiACTA) trial (63). This study was designed to assess 
if tocilizumab led to higher rates of sustained glucocorticoid-free remission of GCA 
than placebo through a period of 52 weeks (63). The GiACTA trial included 251 
patients from 14 countries and 76 centers, 61 of them from Europe and 15 from North 
America. Newly diagnosed (n= 119) and relapsing (n= 132) GCA patients were 
included in the study if they had histological findings of GCA in the temporal artery 
biopsy or had imaging techniques showing large-vessel vasculitis and disease activity 
(cranial symptoms or polymyalgia rheumatica with increased acute-phase reactants). 
Patients recruited in this trial were included in one of the four groups: a weekly dose of 
162 mg of subcutaneous tocilizumab plus a 26-week prednisone taper (n= 100), a dose 
of f 162 mg of subcutaneous tocilizumab given every other week along with a 26-week 
prednisone taper (n= 50), a third group of weekly placebo-treated patients along with a 
26-week prednisone taper (n= 50), and a fourth group of weekly placebo-treated plus a 
52-week prednisone taper (n=51). 
Tocilizumab-treated patients experienced sustained remission more commonly than 
those placebo-treated at 52-week. Whereas 56% of the patients receiving subcutaneous 
tocilizumab every week and 53% of those treated with subcutaneous tocilizumab every 
other week achieved remission, only 14% and 18% of the patients treated with placebo 
plus 26-week prednisone taper or 52-week prednisone taper reached sustained remission 
(63). The difference was statistical significance. Also, tocilizumab-treated patients had 
lower frequency of relapses of the disease (23% and 26% in those treated with 
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tocilizumab every week or every other week) than those included in the 26 and 52-week 
placebo arms (68% and 49%, respectively). Patients undergoing tocilizumab therapy 
had longer duration of remission free of relapses than those treated with placebo. 
Tocilizumab use was associated with a powerful glucocorticoid-sparing effect (63). This 
effect was stronger in the patients who had suffered relapses before randomization. 
Tocilizumab-treated patients had less serious adverse events than those treated with 
placebo (63).  
Due to the positive results obtained in the GiACTA trial, the United States FDA and the 
European Commission have approved the weekly use of subcutaneous tocilizumab for 
the management of GCA (Figure 2). Nevertheless, the GiACTA trial has several 
limitations (57,64). With respect to this, half of the patients from this trial had short 
disease duration as the inclusion in the study for newly diagnosed patients was made 
within the first six weeks after the disease diagnosis. Another potential point of concern 
was the definition of remission, which was considered as the absence of relapse (flare) 
plus normalization of the CRP. Since tocilizumab yields a marked reduction of acute 
phase reactants, it is difficult to determine whether the effect mediated by this agent 
leads to a true remission of this vasculitis without having histopathology or imaging 
exams supporting such an improvement (57,64). In this regard, we and others have 
observed persistent FDG uptake in large blood vessels from patients with GCA who are 
clinically asymptomatic with normal ESR and CRP (99). Another potential limitation of 
the GiACTA trial was the scarce information on the effect of tocilizumab on visual loss, 
due to the small number of patients with unilateral or bilateral blindness at the time of 
inclusion.  
Several open-label studies indicate that tocilizumab may also be useful for the 
management of refractory patients with other types of large vessel vasculitis. 
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Tocilizumab yielded beneficial effects in patients with isolated aortitis and Takayasu´s 
arteritis, who were refractory to glucocorticoids and in many cases to other 
immunosuppressive agents (100,101).   
We have recently conducted an observational, open-label multicenter study that 
included 134 GCA patients from 40 Spanish referral centers. All of them were treated 
with tocilizumab due to inefficacy or adverse events of previous therapies (102).   
Tocilizumab yielded rapid and maintained clinical and laboratory improvement, 
regardless of GCA time course (less than 6 months or more than 6 months), 
administration route (intravenous of subcutaneously) or prednisone dose at the onset of 
tocilizumab (≤ 15 mg/day or > 15 mg/day). The results from this large series of real-
world patients were in agreement with data from the randomized control trials. 
According to our results, tocilizumab seems to be an excellent therapeutic option in 
patients with refractory GCA, regardless of the administration route and GCA duration, 
helping to minimize the glucocorticoid exposure over time (102). However, we 
observed a higher frequency of serious infections than in the GiACTA clinical trial and 
in patients with rheumatoid arthritis, especially in those GCA patients on higher doses 
of prednisone during the first three months of tocilizumab treatment (102). We think 
that the older age as well as the higher prednisone dose used in our series of GCA 
patients at the time of tocilizumab onset may explain the increased frequency of serious 
infections when compared with rheumatoid arthritis (102). We feel that the age of the 
patients, the cumulative dose of glucocorticoids and the presence of comorbidities that 
predispose to infections should be considered before using tocilizumab in the clinical 
practice (102). 
There are other anti-IL-6 monoclonal antibodies, different from tocilizumab, currently 
under investigation in GCA. A phase-3 randomized, controlled, double-blind study 
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using sirukumab, a fully human anti-IL-6 IgG1 antibody that blocks the IL-6 pathway 
(ClinicalTrials.gov Identifier: NCT02531633) was initiated but it was cancelled. Also, 
sarilumab, another anti-IL-6R agent, is under study for its potential use and safety in 
GCA (ClinicalTrials.gov Identifier: NCT03600805).  
3.2.2.3. Cytotoxic T lymphocyte antigen 4-immunoglobulin-Abatacept  
Following T cell activation, T cells express a molecule called cytotoxic T lymphocyte 
antigen 4 (CTLA-4) that competes with CD28 for the binding to CD80 and CD86, 
playing a role as a T cell co-stimulus inhibitor (103). Since affinity of the CD80/CD86 
receptors is higher for CTLA-4 than for CD28, impairment of T cell activation can be 
achieved by using a soluble CTLA-4 engineered molecule. In this regard, the 
recombinantIg-CTLA-4 molecule abatacept, a dimeric fusion protein composed of the 
crystallizable fragment of a human IgG1 and the extracellular domain of CTLA-4, 
creates a soluble receptor able to bind with high-affinity CD80/CD86 molecules 
blocking its interaction with CD28, leading to a decrease of T cell activation (104). 
Interestingly, some reports described patients treated with the biologic agent ipilimumab 
for malignant melanoma that developed GCA (105). Ipilimumab is a monoclonal 
antibody directed against the CTLA-4 expressed on the surface of activated T cells 
(105). Taken together these findings, it was plausible to think that abatacept might be 
useful in the management of patients with GCA, Because of that, to determine safety 
and efficacy of abatacept to maintain remission of GCA, patients with newly-diagnosed 
or relapsing GCA were treated with 10 mg/kg intravenously of abatacept on days 1, 15, 
29, and at week 8, together with prednisone (106). At week 12, 41 patients who had 
achieved remission were blindly randomized to receive either monthly placebo 
intravenous infusions (n=21) or monthly intravenous abatacept (n=20). Patients 
included in both study arms performed a standardized tapering prednisone dose until 
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discontinuation at week 28. Interestingly, the median duration of remission was 
significantly longer in abatacept-treated patients (9.9 months versus 3.9 months in those 
who received intravenous placebo). The primary outcome of the study, relapse-free 
survival at 12 months, was also significantly more common in patients treated with 
intravenous abatacept (48%) than in those treated with placebo (31%) (106). There were 
no differences in side effects between abatacept and placebo-treated groups (106).  
However, some investigators have pointed out that due to the nonstandard design, in 
particular on glucocorticoid management, this study cannot be compared with the 
standard of care (107). Moreover, another point that limits our ability to generalize the 
results of this study is the small number of patients assessed (n= 41). Therefore, further 
studies encompassing larger number of patients are needed to confirm whether 
abatacept is useful as adjunctive treatment to reduce relapses or as a 
glucocorticoid‐ sparing agent in patients with GCA. 
3.2.2.4. Selective target of interleukin-12 (IL-12) and interleukin 23-Ustekinumab 
IL-12 and IL-23 are two key cytokines involved in the anomalous Th1 and Th17 
response implicated in the pathogenesis of GCA. Ustekinumab is a monoclonal 
antibody that acts targeting both IL-12 and IL-23 pathways. It leads to a disruption of 
the Th1 (IL-12) and Th17 (IL-23) immune responses. The administration of three 
injections of 45 mg of ustekinumab given at weeks 0, 4 and 16 led to a significant 
reduction of Th1 and Th17 cells and cytotoxic T lymphocytes at peripheral blood when 
compared to baseline in patients with refractory GCA (106). A significant increase of 
Tregs was also observed (108).  
Ustekinumab was given to 14 GCA patients with long disease duration (median 30 
months). These patients had been unable to taper glucocorticoids due to active GCA 
with a minimum of two relapses. In this open-label study, ustekinumab was prescribed 
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at 90 mg subcutaneously at weeks 0, week 4 and then every 12 weeks (median 8 
months) (109). Ustekinumab use allowed to reduce the glucocorticoid dose (109). Also, 
glucocorticoids were successfully discontinued in 3 patients and in 8 patients 
ustekinumab allowed the discontinuation of the baseline immunosuppressive agents. 
Although there were not relapses while the patients were undergoing ustekinumab 
therapy, relapses were common following ustekinumab discontinuation.  
An open label study to test the safety and efficacy of ustekinumab in patients with GCA 
is underway (estimated study completion date March 2020). 
3.2.2.5. Anti-IL-1β agents 
Increased of IL-1β mRNA expression was also observed in the temporal arteries of 
patients with biopsy-proven GCA. Because of that, IL-1β antagonists have been 
proposed as potential agents to be used in the management of GCA.  
A recombinant and slightly modified version of the human IL-1 receptor antagonist 
protein- anakinra was used at a dose of 100 mg/day in three patients with refractory 
GCA (110). Since it yielded favorable results, a phase-3 study is intended to be 
performed to assess its efficacy in GCA (NCT02902731). 
Gevokizumab, a recombinant humanized anti-IL-1β antibody, is also under 
investigation for the management of GCA (European Clinical Trials Database Identifier 
2013–002778–38). 
3.2.2.6. Janus kinase (JAK) inhibitors 
JAK inhibitors act inhibiting the activity of one or more of the Janus kinase family of 
enzymes (JAK1, JAK2, JAK3, TYK2). A great number of cytokines that are immune 
relevant mediators use the Janus kinase/signal transducers and activators of 
transcription (JAK/STAT) pathway to transduce intracellular signals (111). Ligand 
binding of these immune mediators to their cell surface receptors leads to activation of 
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associated JAKs. The activated JAKs increase their kinase activity, recruit, bind and 
activate STAT. The STAT molecules constitute hetero- or homo-dimers which 
translocate to the nucleus, inducing transcription and expression of target genes. 
Polymorphisms of JAK and STAT genes have been associated with autoimmune 
diseases (111).  STAT-1 signaling regulates the activity of vascular dendritic cells, 
controlling T cell trafficking and retention of inflammatory T cells in the vascular 
lesions (112,113). IFN-γ is the major inducer of STAT-1. In an experimental model in 
immunodeficient mice, in which animals were engrafted with human medium-sized 
arteries and then reconstituted with peripheral blood mononuclear cells from patients 
with biopsy-proven GCA, dexamethasone suppressed the innate immunity with 
inhibition of dendritic cell activation, IL-6 and IL-1β expression in the vascular lesions. 
However, dexamethasone spared adaptive immunity and left IFN-γ-producing Th1 
unaffected (112). The JAK/STAT-inhibitor tofacitinib, a kinase inhibitor for JAK1 and 
JAK3, prevented T cell accumulation in the vessel wall and suppressed IFN-γ 
production and signaling in a model of vascular inflammation in human arteries 
engrafted into immunodeficient mice that were reconstituted with T cells and 
monocytes from patients with GCA (112,113). 
Baricitinib is an orally bioavailable inhibitor of JAK1 and JAK2 that inhibits Th17 (IL-
6, IL23) and Th1 (IL-12, IFN-γ) pathways. A phase-II open-label pilot study with 
baricitinib is currently recruiting patients with relapsing GCA (NCT03026504) whose 
estimated primary completion results will be presented by June 2020. 
 
4. Conclusions 
GCA is the most common vasculitis in elderly people from Western countries. It may 
lead to serious and irreversible complications, including permanent visual loss. 
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Glucocorticoids represent the cornerstone therapy for GCA. They yield excellent 
response in most patients if they are given soon before the onset of visual 
complications. However, relapses are frequent when glucocorticoids are tapered and the 
prolonged used of glucocorticoids is associated with increased risk of complications, 
such as diabetes, osteoporosis, hypertension or infection. This has been the reason for 
the search for alternative therapies that may shorten the duration of glucocorticoids and 
may help clinicians to taper prednisone, in particular in patients with refractory or 
relapsing disease.   
MTX is the conventional immunosuppressive agent most commonly used in patients 
with refractory GCA. However, comprehensive reviews indicate that the benefits 
associated with the use of MTX are modest.  Novel biologic therapies that were 
previously used in rheumatoid arthritis and other autoimmune diseases have also been 
used in GCA. Unlike anti-TNF-α agents that yielded negative results, the anti-IL-6R-
tocilizumab has proved to be effective in newly diagnosed and also in relapsing patients 
with GCA. Daily clinical practice reports support the claim that tocilizumab is 
especially useful in patients with refractory disease. The use of this biologic agent leads 
to reduction of the cumulative glucocorticoid dose and the frequency of relapses of the 
disease. Because of that, tocilizumab has been approved for the management of GCA. 
Nevertheless, autopsy results have shown persistent vascular inflammation in patients 
who were apparently in clinical remission following tocilizumab therapy (114).  
Other monoclonal antibodies, such as abatacept and ustekinumab, have shown 
promising preliminary results that need to be confirmed in clinical trials. The efficacy of 
JAK/STAT inhibitors in the management of GCA is currently under investigation.  
Graphical abstract shows the main clinical features and therapeutic options of both 
classical (cranial) and extracranial phenotypes of GCA.  
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FIGURE LEGENDS 
Figure 1. Immunopathogenesis of giant cell arteritis. Main molecular and cellular lines 
implicated in the pathogenesis of GCA. 
Abbreviations: CCL: chemokines (CC family); CD: cluster of differentiation; CXCL: 
chemokines (CXC family); DCs: dendritic cells; ET-1: endothelin 1; GCA: giant cell 
arteritis; GFs: growth factors; IL: interleukin; IFN-ϒ: interferon gamma; TLRs: toll like 
receptors; MAMPs: microorganism-associated molecular patterns; MHC: major 
histocompatibility complex; MMPs: matrix metalloproteinases; PAMPs: pathogen 
associated molecular patterns; PDGF: platelet-derived growth factor; TAB: temporal 
artery biopsy; TGF-β: transforming growth factor beta; Th: T helper lymphocytes; Treg: 
T regulators lymphocytes; VEGF: vascular endothelial growth factor; VSMC: vascular 
smooth muscle cells. 
 
Figure 2. Stepped therapeutical proposal for the treatment of giant cell arteritis. 
Abbreviations: IFN- ϒ: interferon gamma; IL-6R: interleukin-6 receptor; JAK: Janus 
kinase; STAT: signal transducers and activators of transcription. 
 
Graphical abstract. Schematic view of the different clinical features and therapeutic 
options for both classical (cranial) and extracranial phenotypes of giant cell arteritis. 
Abbreviations: GCA: giant cell arteritis; PET/CT: positron emission 
tomography/computed tomography-scan.  
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Table 1. Symptoms, clinical features and alarm signs of GCA. 
____________________________________________________________ 
A) Typical cranial ischemic manifestations 





Unexplained dry cough 
Temporal artery abnormalities on physical examination 
Acute visual deficits 
Anterior ischemic optic neuropathy or central retinal artery occlusion on
ophthalmologic examination 
B) Associated constitutional symptoms 
C) Associated polymyalgia rheumatica symptoms* 
D) Associated anemia an elevated C reactive protein/erythrocyte sedimentation rate 
E) Extra-cranial disease 
Ischemic signs and symptoms of extremities, especially in the absence of other 
cardiovascular risk factors or emboligenic cardiopathy: 
  Limb claudication 
  Pulse asymmetry 
  Arterial pressure asymmetry 
  Peripheral arterial bruits 
  Distal necrosis or gangrene 
F) Non-specific manifestations without evidence of infectious o neoplastic disease: 
 Fever 
 Weight loss 
 Fatigue/malaise 
 Unexplained anemia 
G Detection of aneurysm or dissection of aorta and main branches along with raised 
inflammatory markers 
______________________________________________________________________ 
*Polymyalgia rheumatica that relapses or responds poorly to standard glucocorticoid 
therapy 
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Table 2. Main drugs used in the management of giant cell arteritis. 
__________________________________________________________________ 
Glucocorticoids (gold standard therapy) 
 Most commonly prednisone/prednisolone: Initial dose:  40- 60 mg/day 
 Methylprednisolone pulses (in patients with visual ischemic complications) 
 
Methotrexate as glucocorticoid-sparing agent (moderate efficacy) 
 
Anti-IL-6R-tocilizumab (first drug approved to treat giant cell arteritis) 
In newly diagnosed patients  
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